Biosimilar Entry and the Pricing of Biologic Drugs
Year of publication: |
[2021]
|
---|---|
Authors: | Maini, Luca ; Feng, Josh ; Hwang, Thomas ; Klimek, Jacob |
Publisher: |
[S.l.] : SSRN |
Subject: | Markteintritt | Market entry | Arzneimittel | Pharmaceuticals | Pharmaindustrie | Pharmaceutical industry | Theorie | Theory | Arzneimittelmarkt | Pharmaceutical market |
Extent: | 1 Online-Ressource (49 p) |
---|---|
Type of publication: | Book / Working Paper |
Language: | English |
Notes: | Nach Informationen von SSRN wurde die ursprüngliche Fassung des Dokuments January 4, 2021 erstellt |
Other identifiers: | 10.2139/ssrn.3760213 [DOI] |
Source: | ECONIS - Online Catalogue of the ZBW |
-
Product line extensions under the threat of entry: evidence from the UK pharmaceuticals market
Bokhari, Farasat A. S., (2020)
-
Optimal patent policy for pharmaceutical industry
Izhak, Olena, (2020)
-
Consumer learning and the entry of generic pharmaceuticals
Bairoliya, Neha, (2017)
- More ...
-
Mergers that Matter : The Impact of M&A Activity in Prescription Drug Markets
Feng, Josh, (2023)
-
Profiting from Most-Favored Customer Procurement Rules : Evidence from Medicaid
Feng, Josh, (2020)
-
Profiting from most-favored-customer procurement rules : evidence from medicaid
Feng, Josh, (2023)
- More ...